Scope and challenges of nanoparticle-based mRNA delivery in cancer treatment

IF 6.9 3区医学 Q1 CHEMISTRY, MEDICINAL

Archives of Pharmacal Research Pub Date : 2022-11-24 DOI:10.1007/s12272-022-01418-x

Md. Emranul Karim, Sheikh Tanzina Haque, Hamed Al-Busaidi, Athirah Bakhtiar, Kyi Kyi Tha, Mark M. Banaszak Holl, Ezharul Hoque Chowdhury

{"title":"Scope and challenges of nanoparticle-based mRNA delivery in cancer treatment","authors":"Md. Emranul Karim, Sheikh Tanzina Haque, Hamed Al-Busaidi, Athirah Bakhtiar, Kyi Kyi Tha, Mark M. Banaszak Holl, Ezharul Hoque Chowdhury","doi":"10.1007/s12272-022-01418-x","DOIUrl":null,"url":null,"abstract":"<div><p>Messenger RNA (mRNA) recently emerged as an appealing alternative to treat and prevent diseases ranging from cancer and Alzheimer’s disease to COVID-19 with significant clinical outputs. The in vitro-transcribed mRNA has been engineered to mimic the structure of natural mRNA for vaccination, cancer immunotherapy and protein replacement therapy. In past decades, significant progress has been noticed in unveiling the molecular pathways of mRNA, controlling its translatability and stability, and its evolutionary defense mechanism. However, numerous unsolved structural, biological, and technical difficulties hamper the successful implementation of systemic delivery of mRNA for safer human consumption. Advances in designing and manufacturing mRNA and selecting innovative delivery vehicles are mandatory to address the unresolved issues and achieve the full potential of mRNA drugs. Despite the substantial efforts made to improve the intracellular delivery of mRNA drugs, challenges associated with diverse applications in different routes still exist. This study examines the current progress of mRNA therapeutics and advancements in designing biomaterials and delivery strategies, the existing translational challenges of clinical tractability and the prospects of overcoming any challenges related to mRNA.</p></div>","PeriodicalId":8287,"journal":{"name":"Archives of Pharmacal Research","volume":null,"pages":null},"PeriodicalIF":6.9000,"publicationDate":"2022-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s12272-022-01418-x.pdf","citationCount":"8","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Pharmacal Research","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12272-022-01418-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 8

Abstract

Messenger RNA (mRNA) recently emerged as an appealing alternative to treat and prevent diseases ranging from cancer and Alzheimer’s disease to COVID-19 with significant clinical outputs. The in vitro-transcribed mRNA has been engineered to mimic the structure of natural mRNA for vaccination, cancer immunotherapy and protein replacement therapy. In past decades, significant progress has been noticed in unveiling the molecular pathways of mRNA, controlling its translatability and stability, and its evolutionary defense mechanism. However, numerous unsolved structural, biological, and technical difficulties hamper the successful implementation of systemic delivery of mRNA for safer human consumption. Advances in designing and manufacturing mRNA and selecting innovative delivery vehicles are mandatory to address the unresolved issues and achieve the full potential of mRNA drugs. Despite the substantial efforts made to improve the intracellular delivery of mRNA drugs, challenges associated with diverse applications in different routes still exist. This study examines the current progress of mRNA therapeutics and advancements in designing biomaterials and delivery strategies, the existing translational challenges of clinical tractability and the prospects of overcoming any challenges related to mRNA.

Abstract Image

查看原文本刊更多论文

基于纳米颗粒的mRNA递送在癌症治疗中的范围和挑战

信使RNA (mRNA)最近成为治疗和预防从癌症、阿尔茨海默病到COVID-19等疾病的一种有吸引力的替代方案，并取得了显著的临床成果。体外转录的mRNA已被改造成模拟天然mRNA的结构，用于疫苗接种、癌症免疫治疗和蛋白质替代治疗。近几十年来，在揭示mRNA的分子通路、控制其可译性和稳定性、及其进化防御机制等方面取得了重大进展。然而，许多未解决的结构、生物学和技术难题阻碍了mRNA系统递送的成功实施，从而使人类更安全地食用。设计和制造mRNA以及选择创新的递送工具的进展是解决未解决问题和充分发挥mRNA药物潜力的必要条件。尽管在改善mRNA药物的细胞内递送方面做出了大量努力，但不同途径的不同应用仍然存在挑战。本研究探讨了mRNA治疗学的最新进展、设计生物材料和递送策略的进展、临床可处理性的现有转化挑战以及克服任何与mRNA相关的挑战的前景。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Archives of Pharmacal Research 医学-药学

CiteScore

13.40

自引率

9.00%

发文量

审稿时长

3.3 months

期刊介绍： Archives of Pharmacal Research is the official journal of the Pharmaceutical Society of Korea and has been published since 1976. Archives of Pharmacal Research is an interdisciplinary journal devoted to the publication of original scientific research papers and reviews in the fields of drug discovery, drug development, and drug actions with a view to providing fundamental and novel information on drugs and drug candidates.

文献相关原料

公司名称	产品信息	采购帮参考价格